Abstract: A method for real-time firmware configuration and a debugging apparatus are provided. When a demand for updating or debugging a target processor raises, in the method, a computer system generates a firmware debugging request that is attached with a firmware data with a specific debugging function. The computer system then loads the firmware data to a programmable logic unit of the debugging apparatus. After the real-time firmware configuration is completed, the computer system issues a debugging command to the programmable logic unit. The programmable logic unit obtains at least one debugging action after resolving the debugging command. The at least one debugging action is performed in the target processor when the target processor receives the at least one debugging action. A debugging result is returned after the at least one debugging action is completed.

Abstract: Embodiments of the present disclosure provide methods, systems, apparatuses, and computer program products for generating, training, and utilizing a digital signal processor (DSP) to evaluate graph data that may include irregular grid graph data. An example DSP that may be generated, trained, and used may include a set of hidden layers, wherein each hidden layer of the set of hidden layers comprises a set of heterogeneous kernels (HKs), and wherein each HK of the set of HKs includes a corresponding set of filters selected from the constructed set of filters and associated with one or more initial Laplacian operators and corresponding initial filter parameters.

Abstract: A pharmaceutical composition comprising: a) an effective amount of an Inhibitors of Apoptosis Proteins (IAP) inhibitor, wherein the IAP inhibitor is represented by formula (I): or a pharmaceutically acceptable salt thereof, the definitions of each variable are provided herein; b) an effective amount of a second inhibitor, wherein the second inhibitor is a poly ADP ribose polymerase (PARP) inhibitor or a mitogen-activated protein kinase kinase (MEK) inhibitor; and a pharmaceutically acceptable carrier or diluent.

Abstract: Provided herein is a combination product comprising a Bcl-2 inhibitor and an MDM-2 inhibitor, the combination product providing a use in the prevention and/or treatment of diseases (e.g., cancer).

Abstract: The present invention pertains to the biomedical field, and particularly relates to a method for treating or suppressing a cancer, reducing its severity, lowering its risk or inhibiting its metastasis in an individual. The method comprises administering to the individual a therapeutically effective amount of one or more of a FAK inhibitor, an ALK inhibitor and a ROS1 inhibitor, and a therapeutically effective amount of an EGFR inhibitor. The invention also relates to a pharmaceutical composition or kit comprising one or more of a FAK inhibitor, an ALK inhibitor and a ROS1 inhibitor, and an EGFR inhibitor.

Abstract: Provided herein is a combination product comprising a Bcl-2 inhibitor (or a Bc1-2/Bc1-xl dual inhibitor) and a BTK inhibitor, the combination product providing a use in the prevention and/or treatment of a disease (e.g., cancer, autoimmune disease and inflammatory disease.).

Abstract: A method for real-time firmware configuration and a debugging apparatus are provided. When a demand for updating or debugging a target processor raises, in the method, a computer system generates a firmware debugging request that is attached with a firmware data with a specific debugging function. The computer system then loads the firmware data to a programmable logic unit of the debugging apparatus. After the real-time firmware configuration is completed, the computer system issues a debugging command to the programmable logic unit. The programmable logic unit obtains at least one debugging action after resolving the debugging command. The at least one debugging action is performed in the target processor when the target processor receives the at least one debugging action. A debugging result is returned after the at least one debugging action is completed.

Abstract: Described herein are methods of treating a cancer, for example, a hematologic malignancy or a solid tumor, in a patient in need thereof, comprising administering to the patient a Bcl-2 inhibitor in combination with a second anti-cancer agent.

Abstract: Provided are biomarkers for predicting the efficacy of MDM2 inhibitor or Bcl-2/Bcl-xL dual inhibitors or Bcl-2 inhibitor or Bcl-xL inhibitor in treating cancer patients. Also provided are compositions, e.g., kits, for evaluating gene levels of the biomarkers and methods of using such gene levels to predict a cancer patient's response to the MDM2 inhibitors or Bcl-2/Bcl-xL dual inhibitors or Bcl-2 inhibitor or Bcl-xL inhibitor. Such information can be used in determining prognosis and treatment options for cancer patients.

Abstract: The present invention provides a method for testing and fitting the dihedral angle parameters in force field. The method first generates some representative conformations, and then compares the results of force field and quantum mechanics methods using these structures. If the results meet the predefined standards, the process ends; otherwise the molecule will be cut into small-size molecular fragments with only one flexible dihedral angle in each fragment. The dihedral angles will be scanned. And results of force field and quantum mechanics will be compared for each scanned flexible dihedral angle to find out those that do not meet the standards, and their parameters will be selected for further fitting. After new dihedral angle parameters are obtained, apply them to the original series of conformers of the whole molecule for validation. If results meet the standards, complete the whole process of testing and fitting poorly performing dihedral angle parameters.

Abstract: Disclosed is a pharmaceutical composition comprising (i) a compound of formula (I) or a pharmaceutically acceptable salt thereof; (ii) a CDK inhibitor or a pharmaceutically acceptable salt thereof, for the prevention and/or treatment of a disease mediated by MDM2 and/or CDK activity.

Abstract: Green, fast and easy evaporating organic solvent for use as a lubricant in the processing of polytetrafluoroethylene (PTFE) and expanded polytetrafluoroethylene (ePTFE) products and processes of using the solvents to fabricate the products are disclosed herein. The products can be used in the field of bio- and medical applications, such as for use in vascular grafts, cardiovascular and soft tissue patches, facial implants, surgical sutures, and endovascular prosthesis, and for any products known in the aerospace, electronics, fabrics, filtration, industrial and sealant arts.

Abstract: Provided are biomarkers for predicting the efficacy of BCL-2/BCL-XL dual or selective inhibitors in treating cancer patients. The biomarkers comprise a complex comprising BCL-2 or BCL-XL. Also provided are methods and compositions, e.g., kits, for evaluating levels of the biomarkers and methods of using such levels to predict a cancer patient's response to the BCL-2/BCL-XL dual inhibitors or BCL-XL or BCL-2 inhibitors. Such information can be used in determining prognosis and treatment options for cancer patients.

Abstract: The systems and methods provide a machine learning model that can exploit long time dependency for time-series sequences, perform end-to-end learning of dimension reduction and clustering, or train on long time-series sequences with low computation complexity. For example, the methods and systems use a novel, unsupervised temporal representation learning model. The model may generate cluster-specific temporal representations for long-history time series sequences and may integrate temporal reconstruction and a clustering objective into a joint end-to-end model.

Abstract: The present invention relates to a compound for treating or preventing osteoarthritis. The compound relieves the joint pain, inhibits and attenuates the development of post-traumatic osteoarthritis in mouse model. The present invention also provides a pharmaceutical composition comprising the compound for treating or preventing osteoarthritis. The present invention further provides a method for treating or preventing osteoarthritis by administrating to the patient in need thereof with the pharmaceutical composition.

Abstract: Disclosed herein are combination therapies comprising an effective amount of a modulator of the immune checkpoint molecule; and an effective amount of a MDM2 inhibitor.

Abstract: Green, fast and easy evaporating organic solvent for use as a lubricant in the processing of polytetrafluoroethylene (PTFE) and expanded polytetrafluoroethylene (ePTFE) products and processes of using the solvents to fabricate the products are disclosed herein. The products can be used in the field of bio- and medical applications, such as for use in vascular grafts, cardiovascular and soft tissue patches, facial implants, surgical sutures, and endovascular prosthesis, and for any products known in the aerospace, electronics, fabrics, filtration, industrial and sealant arts.

Abstract: The invention discloses a novel pharmaceutical combination and a use thereof. The pharmaceutical combination comprises a compound of formula (I), a pharmaceutically acceptable salt thereof or a solvate thereof; and a compound of formula (II), a pharmaceutically acceptable salt thereof or a solvate thereof. The pharmaceutical combination can be used to treat cancer.

Abstract: Provided herein are pharmaceutical compositions comprising an MDM2 inhibitor and one or more anti-cancer agents for preventing and/or treating diseases, such as cancer. Methods for preventing and/or treating diseases, such as cancer, comprising administering to the patient in need thereof with the pharmaceutical compositions are also provided.

Abstract: Provided herein is a combination product comprising a Bcl-2/Bcl-xL inhibitor and a chemotherapeutic agent, in particular a Bcl-2/Bcl-xL inhibitor of formula (I-A) and homoharringtonine or an active derivative thereof, in free or pharmaceutically acceptable salt or solvate form. Provided herein is also the use of the aforementioned combination for the preparation of a medicament for the prevention and/or treatment of cancer, in particular of hematological malignancies, and to a method for the prevention and/or treatment of cancer, in particular of hematological malignancies, using the aforementioned combination.